The Grifols family has officially confirmed that it is in preliminary talks with Brookfield Asset Management regarding a potential takeover of the Spanish pharmaceutical company specializing in plasma-derived medicines. The announcement was made Wednesday night through an official statement, shedding light on the nature of the negotiations with the Canadian private equity firm.

According to sources close to the deal, there is a non-negotiable condition for any future acquisition offer: the proposed price must exceed the €10.5 per share that Brookfield suggested back in December. That earlier proposal was rejected by Grifols’ board of directors as inadequate.

The confirmation puts an end to market speculation that had been swirling around the company in recent weeks. While the talks are still at a preliminary stage, they signal a renewed interest from Brookfield in taking over the Spanish biotech firm. However, the Grifols family, which remains a significant shareholder and plays a central role in the company’s strategic decisions, has made it clear that any deal must reflect the true value of the business—especially in light of its long-term potential and recent operational improvements.

The initial bid by Brookfield in November had already sparked debate within financial circles. Many analysts considered the €10.5 per share offer to be below market expectations, particularly given Grifols’ restructuring efforts and plans for international expansion. The rejection by the board suggested that the company believed it could secure a more favorable valuation.

By publicly acknowledging the talks now, the Grifols family is not only confirming the negotiations but also signaling to investors and the broader market that they intend to defend the company’s value. This move may also be aimed at putting pressure on Brookfield to revise its terms if it is serious about pursuing the acquisition.

Grifols, founded in Barcelona and known globally for its plasma-based therapies, has been undergoing a strategic transformation to streamline operations, cut costs, and strengthen its financial standing. These efforts, combined with its global footprint and steady demand for plasma-derived products, are likely to play a key role in determining the company’s valuation in any potential transaction.

While no final decision has been made and there is no guarantee that the talks will lead to a formal offer, the situation remains fluid. Investors and analysts alike will be closely watching how Brookfield responds and whether a new, improved bid will be tabled in the coming weeks.

For now, the message from the Grifols family is clear: if Brookfield wants to make a serious move, it will have to put more money on the table.